Tiziana Life Sciences Ltd
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Tiziana Life Sciences
Pharmaceutical Preparations, SIC 2834
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company focused on developing therapies for oncology and immune-mediated diseases with high unmet medical need. The company concentrates on developing novel drug candidates, primarily monoclonal antibodies targeting immune pathways. Its lead product candidate is Foralumab, which is being investigated across various indications including non-active secondary progressive multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. Additionally, its pipeline includes TZLS-501, an anti-IL6R monoclonal antibody. The company aims to provide treatments for patient populations suffering from neurodegenerative and inflammatory conditions.
The company operates internationally with corporate headquarters situated in Hamilton, Bermuda. Its principal executive offices are located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. In addition to its Bermuda headquarters, Tiziana maintains key executive and contact offices in London, United Kingdom, and conducts operations through subsidiaries spanning Bermuda, the United Kingdom, and the United States.
Summary of the business section of Tiziana Life Sciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Tiziana Life Sciences Ltd
- Headquarters
- London, England, X0
- Address
- 3rd Floor, 11-12 St. James'S Square SW1Y 4LB
- Phone
- 0044(0) 207-495-2379
- Website
- tizianalifesciences.com
- Employees
- 10, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- D0
- Fiscal year ends
- December 31
- Auditor
- PKF Littlejohn LLP, London, England
Stock & identifiers
- Ticker
- TLSA
- Exchange
- Nasdaq
- IPO date
- Nov 21, 2018
- Shares outstanding
- 121M, Dec 31, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 2-for-1, Oct 29, 2019
- SEC CIK
- 1723069
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ivor Elrifi | Chief Executive Officer | 9,648,945 |
| Keeren Rameshchandra Shah | CHIEF OPERATING & FIN. OFFICER | 2,500 |
| Gabriele M. Cerrone | Director | 89,469,417 |
Employees
Headcount reported in annual reports
“had 10 full time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 30, 2026 | Late filing | Notification of late filing |
| Apr 30, 2025 | Late filing | Notification of late filing |
| Apr 30, 2024 | Late filing | Notification of late filing |
| Apr 29, 2022 | Late filing | Notification of late filing |
| Oct 21, 2021 | Name change | Name changed from Tiziana Life Sciences plc to Tiziana Life Sciences Ltd |
| Oct 20, 2021 | Delisting | Notice of delisting from exchange (Form 25) |
| Apr 30, 2021 | Late filing | Notification of late filing |
| Jun 15, 2020 | Late filing | Notification of late filing |
| Nov 21, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 30, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |